Auris Medical (EARS) skyrockets 181% on positive in vitro infection data of COVID

Auris Medical Holding (EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, today announced positive efficacy data from testing AM-301 in vitro. AM-301 is a drug-free nasal spray being developed by the Company’s affiliate Altamira Medica for protection against airborne pathogens and allergens.

AM-301 was tested for its capability to prevent or mitigate SARS-CoV-2 infection of nasal epithelial cells, which are part of the nasal mucosa and the first barrier against continuously inhaled substances such as pathogens and allergens.

The experiment was performed over four days on reconstituted human nasal epithelia, which are frequently used to study the effects of human respiratory viruses. In saline-treated control cultures, Sars-CoV-2 replicated efficiently, resulting in a rapid increase in viral titer (as measured by the Median Tissue Culture Infectious Dose, TCID50).

In contrast, daily treatment with AM-301, beginning right before inoculation, showed effective protection against viral infection. 48 hours post-infection, average virus titers were 90.0% lower than those observed in controls (p<0.05). 72 hours and 96 hours post-infection, average virus titers were 99.2 and 99.4% lower, respectively (p<0.001).

Even when unbound virus was not removed daily through apical washing, allowing the virus to accumulate in the culture for 4 days, the reduction in viral titer was 92.4% compared to saline-treated controls (p<0.001).  

“We are very excited to see the protective effects of AM-301 against Sars-CoV-2 confirmed in an assay that very closely replicates real-life conditions in the human nose, Our first experiments in September showed that AM-301’s key component trapped up to 99% of Sars-CoV-2 when brought into contact with a viral suspension. Now, with our newly developed spray formulation, we have direct evidence that AM-301 has the potential to significantly mitigate the risk of infection of nasal mucosal cells. We look forward to taking AM-301 through additional tests and advancing the program towards the submission of regulatory applications in 2021.”

What is Auris Medical’s AM-301?

AM-301 is a drug-free nasal spray for personal protection against airborne pathogens and allergens. Upon application into the nose, AM-301 forms a protective gel layer on the nasal mucosa. This thin film is designed to prevent the contact of viruses or other pathogens and allergens with cells; in addition, the composition serves to “trap” such particles and help with their discharge. Together, this is designed to reduce the risk of upper respiratory infections and promote alleviation of allergic symptoms.

Other breakthrough companies you can invest in that is fighting COVID-19

Relief Therapeutics (OTC:RLFTF)

Relief Therapeutic’s RLF-100 is safer than vaccines. In the open-label prospective study, more rapid recovery was seen among 21 patients treated with RLF-100 than those treated with standard of care with an average of nine fewer ICU days in the RLF-100 treated patients compared to those treated with Standard of Care.

Aytu Bioscience (AYTU)

To fight COVID-19, this company uses a technology called Healight. The CEO Josh Disbrow acknowledged that the company is working with Healight and the FDA at a rapid pace. The clinical studies are expected to be announced soon with the cooperation with leading centers in Europe.


Little known stock to put $25 in RIGHT NOW!

The electric vehicle boom is just getting started… and we have just uncovered one of the most profitable company that’s about to go public through a SPAC. Even Wall Street is excited, calling it “A promising challenger to Tesla”, they even called it “Electric vehicle gold.”

Subscribe below and don’t miss out on this opportunity!

Default image
Tim Rolle
Investor of 6 years and Managing Editor of Money Midnight, a news outlet focused on highly profitable investment ideas and bold underground research.
Articles: 113

Newsletter Updates

Enter your email address below to subscribe to our newsletter